Lite Strategy, Inc. (LITS) Stock Price & Analysis

Lite Strategy, Inc. (LITS) rose 0.19% to USD 0.76 as of June 10, 2026 at 09:34 UTC, according to Nexqual real-time market data.

LITS last closed at USD 0.75; the session ranged USD 0.72–0.79 on volume of 467,270 shares. Market capitalization is $25.73M, with a 52-week range of USD 0.7–9 (NCM). Source: Nexqual, June 10, 2026 at 09:34 UTC.

Key Statistics (as of June 10, 2026 at 09:34 UTC)

Technical Analysis (LITS)

Nexqual's technical model rates LITS "SELL" based on 2 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:34 UTC.

Analyst Ratings (LITS)

Wall Street analysts rate LITS "None", per Nexqual as of June 10, 2026 at 09:34 UTC.

Earnings (LITS)

Recent Earnings History

Source: Nexqual, June 10, 2026 at 09:34 UTC.

Financials & Fundamentals (LITS)

Source: Nexqual, June 10, 2026 at 09:34 UTC.

Financial Health Score (LITS)

Nexqual rates Lite Strategy, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 09:34 UTC.

Ownership (LITS)

Source: Nexqual, June 10, 2026 at 09:34 UTC.

Leadership (LITS)

Lite Strategy, Inc. is led by Justin J. File (age 55), CEO, CFO, Corporate Secretary & Director, per Nexqual as of June 10, 2026 at 09:34 UTC.

Major Backers & Investors (LITS)

Notable institutional backers of Lite Strategy, Inc. include Renaissance Technologies, Citadel, Two Sigma Investments, LP, according to Nexqual as of June 10, 2026 at 09:34 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 10, 2026 at 09:34 UTC.

From Lite Strategy, Inc.'s Latest SEC 10-K Filing (filed 2025-09-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Following the November meeting, the companies jointly concluded that a clinical trial consistent with the recent FDA guidance, including 8 Table of Contents   modification of the COASTAL trial, would likely not be feasible to complete within a time period that would support further investment or with sufficient certainty of the regulatory requirements for approval to justify continued global development efforts.
• The process required by the FDA before drugs may be marketed in the U.S. generally involves the following: • nonclinical laboratory evaluations, including formulation and stability testing and animal tests performed under the FDA's Good Laboratory Practices (GLP) regulations to assess pharmacological activity and toxicity potential.
• Generally, the FDA may not approve an abbreviated new drug application (ANDA) or 505(b)(2) NDA unless the reference listed drug's Orange Book listed patents have expired and/or if the applicant certifies that it is not seeking approval for a patented method of use.
• Our success depends in large part on our ability to protect our proprietary technologies, compounds and information and to operate without infringing the proprietary rights of third parties.

Partnerships

• In addition, we entered into a consulting agreement with Mr.
• Zandelisib: PI3Kδ Inhibitor Overview Zandelisib is an oral, once-daily, selective PI3Kδ inhibitor that we were jointly developing with Kyowa Kirin Co., Ltd (KKC) under a global license, development and commercialization agreement entered into in April 2020 that was later terminated in 2023 (as further discussed below).

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:34 UTC. This page is informational and not investment advice.